We identified eight trials evaluating the efficacy of GLP-1 RAs in reducing glucose levels and weight in patients with T2DM: DURATION-1, LEAD-6, DURATION-5, DURATION-6, HARMONY-7, AWARD-6, SUSTAIN-3, and SUSTAIN-10. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.